Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours
Geert Spierenburg(Leiden University Medical Center), Hans Gelderblom(Leiden University Medical Center), David Pérol(Centre Léon Bérard), Séverine Metzger(Centre de Recherche en Cancérologie de Lyon), Peter Grimison(The University of Sydney), Michiel A. J. van de Sande(Leiden University Medical Center), Virginia Ferraresi(Cancer Institute (WIA)), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Sylvie Chabaud(Centre de Recherche en Cancérologie de Lyon), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Florence Duffaud(Aix-Marseille Université), L. van der Heijden(Leiden University Medical Center), Axel Le Cesne(Institut Gustave Roussy), Christine Chevreau(Institut Claudius Regaud), Sophie Piperno‐Neumann(Institut Curie)
Cited by 33
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k